Drug companies tend to offer investors some of the highest dividend yields from the healthcare sector. But only two of seven pharmaceutical stocks currently yielding more than 3% are worth buying.
It's a showdown between the healthcare conglomerate and the diabetes pioneer.
A collection of underperforming stocks held by Soros Fund Management that could be set to bounce strongly.
Here's a look at the reasons why shares of Cempra jumped last month.
The murky acquisition of Stemcentryx and its lung cancer candidate, Rova-T, just became a much clearer.
AbbVie's risk profile has ballooned over the past year. Here's why.
Slowing sales growth for the company's hepatitis C drugs may have some Wall Street money managers cautious, but with the company's shares on sale, everyday investors may find that there's value in buying this beaten-up biotech.
Pfizer's acquisition of Anacor shows M&A is alive and well for biotech companies with late-stage research programs.
Sarepta Therapeutics, Synergy Pharmaceuticals, and Celator Pharmaceuticals all hope to have drugs on the market soon.
Venclexta's approval in CLL is important, but another drug making its way to market could reduce its use someday.